Inventiva S.A.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filer
State of Incorporation
France
Business Address
50 RUE DE DIJON, DAIX, I0, 21121
Mailing Address
50 RUE DE DIJON, DAIX, I0, 21121
Phone
33380447500
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | April 8, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | March 30, 2026 | View on SEC |
| 6-K Foreign company current report | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| 6-K Foreign company current report | November 28, 2025 | View on SEC |
Annual Reports
20-F
April 8, 2026
- Advancing lead drug candidate lanifibranor through pivotal Phase III NATiV3 clinical trials.
- Secured €94 million in capital through private sales and debt to extend operational runway.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.